The high cost of prescription drugs is a hot topic in the U.S., a factor likely on the minds of Amgen executives in setting the price of a new treatment for Migraine headaches.

Although that might seem expensive, especially if the drug isn't covered by insurance, the pricing drew praise from Express Scripts, the biggest U.S. pharmacy benefit manager (PBM).

Express Scripts has previously urged Amgen to rethink its approach of setting a high list price for new medications and then cutting the cost for health plans by offering large rebates.

Critics of PBMs blame them for contributing to the surge in prescription drug costs in recent years, especially the practice of offering rebates to pharmaceutical firms.

President Trump vowed last week to "bring soaring drug prices back down to earth ," specifically by reining in "middlemen" like Express Scripts.

"I think we see the decision taken in the U.S. to price absolutely responsibly," Novartis Pharmaceuticals CEO Paul Hudson said in a call with analysts on Friday to discuss the medication.

"Aimovig provides patients with a novel option for reducing the number of days with migraine," Dr. Eric Bastings, deputy director of the Division of Neurology Products in the FDA's Center for Drug Evaluation and Research, said in a statement .